{
    "id": 22155,
    "fullName": "MET dec exp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "MET dec exp indicates decreased expression of the Met protein and/or mRNA. However, the mechanism causing the decreased expression is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 4233,
        "geneSymbol": "MET",
        "terms": [
            "MET",
            "AUTS9",
            "c-Met",
            "DFNB97",
            "HGFR",
            "RCCP2"
        ]
    },
    "variant": "dec exp",
    "createDate": "05/03/2016",
    "updateDate": "10/08/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 6142,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, triple-receptor negative breast cancer cell lines with decreased Met expression via shRNA knockdown demonstrated increased sensitivity to Lynparza (olaparib) induced growth and colony formation inhibition in culture (PMID: 26779812).",
            "molecularProfile": {
                "id": 22706,
                "profileName": "MET dec exp"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5319,
                    "pubMedId": 26779812,
                    "title": "Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26779812"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6143,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, triple-receptor negative breast cancer cell lines with decreased Met expression via shRNA knockdown demonstrated increased sensitivity to Veliparib (ABT-888) induced growth and colony formation inhibition in culture (PMID: 26779812).",
            "molecularProfile": {
                "id": 22706,
                "profileName": "MET dec exp"
            },
            "therapy": {
                "id": 954,
                "therapyName": "Veliparib",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5319,
                    "pubMedId": 26779812,
                    "title": "Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26779812"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6144,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, triple-receptor negative breast cancer cell lines with decreased Met expression via shRNA knockdown demonstrated increased sensitivity to Rubraca (rucaparib) induced growth and colony formation inhibition in culture (PMID: 26779812).",
            "molecularProfile": {
                "id": 22706,
                "profileName": "MET dec exp"
            },
            "therapy": {
                "id": 906,
                "therapyName": "Rucaparib",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5319,
                    "pubMedId": 26779812,
                    "title": "Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26779812"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6148,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, decreasing Brca1 expression via shRNA knockdown sensitized triple-receptor negative breast cancer cells with low expression of Met to Rubraca (rucaparib) in culture (PMID: 26779812).",
            "molecularProfile": {
                "id": 22726,
                "profileName": "BRCA1 dec exp MET dec exp"
            },
            "therapy": {
                "id": 906,
                "therapyName": "Rucaparib",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5319,
                    "pubMedId": 26779812,
                    "title": "Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26779812"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6149,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, decreasing Brca2 expression via shRNA knockdown sensitized triple-receptor negative breast cancer cells with low expression of Met to Rubraca (rucaparib) in culture (PMID: 26779812).",
            "molecularProfile": {
                "id": 22728,
                "profileName": "BRCA2 dec exp MET dec exp"
            },
            "therapy": {
                "id": 906,
                "therapyName": "Rucaparib",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5319,
                    "pubMedId": 26779812,
                    "title": "Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26779812"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6156,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, decreasing Met expression via shRNA knockdown did not sensitize triple-receptor negative breast cancer cells overexpressing PARP1 Y907F to Veliparib (ABT-888) in culture (PMID: 26779812).",
            "molecularProfile": {
                "id": 22733,
                "profileName": "MET dec exp PARP1 Y907F"
            },
            "therapy": {
                "id": 954,
                "therapyName": "Veliparib",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 5319,
                    "pubMedId": 26779812,
                    "title": "Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26779812"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6154,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, decreasing Met expression via shRNA knockdown did not sensitize triple-receptor negative breast cancer cells overexpressing PARP1 Y907F to Rubraca (rucaparib) in culture (PMID: 26779812).",
            "molecularProfile": {
                "id": 22733,
                "profileName": "MET dec exp PARP1 Y907F"
            },
            "therapy": {
                "id": 906,
                "therapyName": "Rucaparib",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 5319,
                    "pubMedId": 26779812,
                    "title": "Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26779812"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6153,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, decreasing Met expression via shRNA knockdown did not sensitize triple-receptor negative breast cancer cells overexpressing PARP1 Y907E to Rubraca (rucaparib) in culture (PMID: 26779812).",
            "molecularProfile": {
                "id": 22734,
                "profileName": "MET dec exp PARP1 Y907E"
            },
            "therapy": {
                "id": 906,
                "therapyName": "Rucaparib",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 5319,
                    "pubMedId": 26779812,
                    "title": "Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26779812"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6155,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, decreasing Met expression via shRNA knockdown did not sensitize triple-receptor negative breast cancer cells overexpressing PARP1 Y907E to Veliparib (ABT-888) in culture (PMID: 26779812).",
            "molecularProfile": {
                "id": 22734,
                "profileName": "MET dec exp PARP1 Y907E"
            },
            "therapy": {
                "id": 954,
                "therapyName": "Veliparib",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 5319,
                    "pubMedId": 26779812,
                    "title": "Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26779812"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6152,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, decreasing Met expression via shRNA knockdown sensitized triple-receptor negative breast cancer cells overexpressing wild-type Parp1 to Rubraca (rucaparib) in culture (PMID: 26779812).",
            "molecularProfile": {
                "id": 22735,
                "profileName": "MET dec exp PARP1 wild-type"
            },
            "therapy": {
                "id": 906,
                "therapyName": "Rucaparib",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5319,
                    "pubMedId": 26779812,
                    "title": "Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26779812"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6157,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, decreasing Met expression via shRNA knockdown sensitized triple-receptor negative breast cancer cells over expressing wild-type Parp1 to Veliparib (ABT-888) in culture (PMID: 26779812).",
            "molecularProfile": {
                "id": 22735,
                "profileName": "MET dec exp PARP1 wild-type"
            },
            "therapy": {
                "id": 954,
                "therapyName": "Veliparib",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5319,
                    "pubMedId": 26779812,
                    "title": "Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26779812"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8671,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, knocking down of Met expression via shRNA sensitized colorectal cancer cells harboring both BRAF mutations and NF1 inactivating mutations to PLX4720 in culture (PMID: 26351322).",
            "molecularProfile": {
                "id": 26399,
                "profileName": "BRAF mut MET dec exp NF1 inact mut"
            },
            "therapy": {
                "id": 1060,
                "therapyName": "PLX4720",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6708,
                    "pubMedId": 26351322,
                    "title": "Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26351322"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12260,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Rogaratinib (BAY 1163877) inhibited Erk signaling and proliferation of FGFR1-amplified lung cancer cell lines with undetectable Met expression in culture (PMID: 27429073).",
            "molecularProfile": {
                "id": 28613,
                "profileName": "FGFR1 amp MET dec exp"
            },
            "therapy": {
                "id": 2030,
                "therapyName": "Rogaratinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9936,
                    "pubMedId": 27429073,
                    "title": "Activation of the Met kinase confers acquired drug resistance in FGFR-targeted lung cancer therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27429073"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12258,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD4547 inhibited Erk signaling and proliferation of FGFR1-amplified lung cancer cell lines with undetectable Met expression in culture (PMID: 27429073).",
            "molecularProfile": {
                "id": 28613,
                "profileName": "FGFR1 amp MET dec exp"
            },
            "therapy": {
                "id": 654,
                "therapyName": "AZD4547",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9936,
                    "pubMedId": 27429073,
                    "title": "Activation of the Met kinase confers acquired drug resistance in FGFR-targeted lung cancer therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27429073"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 22706,
            "profileName": "MET dec exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 22726,
            "profileName": "BRCA1 dec exp MET dec exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 22728,
            "profileName": "BRCA2 dec exp MET dec exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 22733,
            "profileName": "MET dec exp PARP1 Y907F",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 22734,
            "profileName": "MET dec exp PARP1 Y907E",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 22735,
            "profileName": "MET dec exp PARP1 wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26399,
            "profileName": "BRAF mut MET dec exp NF1 inact mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28613,
            "profileName": "FGFR1 amp MET dec exp",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}